Accepted Manuscript

New *ent*-kauranes from the fruits of *Annona glabra* and their inhibitory nitric oxide production in LPS-stimulated RAW264.7 macrophages

Nguyen Xuan Nhiem, Nguyen Thi Thu Hien, Bui Huu Tai, Hoang Le Tuan Anh, Dan Thi Thuy Hang, Tran Hong Quang, Phan Van Kiem, Chau Van Minh, Wonmin Ko, Seungjun Lee, Hyuncheol Oh, Seung Hyun Kim, Young Ho Kim

PII:	S0960-894X(14)01254-2
DOI:	http://dx.doi.org/10.1016/j.bmcl.2014.11.059
Reference:	BMCL 22214
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date:	29 August 2014
Revised Date:	6 November 2014
Accepted Date:	20 November 2014



Please cite this article as: Nhiem, N.X., Hien, N.T.T., Tai, B.H., Anh, H.L.T., Hang, D.T.T., Quang, T.H., Van Kiem, P., Van Minh, C., Ko, W., Lee, S., Oh, H., Kim, S.H., Kim, Y.H., New *ent*-kauranes from the fruits of *Annona glabra* and their inhibitory nitric oxide production in LPS-stimulated RAW264.7 macrophages, *Bioorganic & Medicinal Chemistry Letters* (2014), doi: http://dx.doi.org/10.1016/j.bmcl.2014.11.059

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Bioorg. Med. Chem. Lett.

New ent-kauranes from the fruits of Annona glabra and their inhibitory

nitric oxide production in LPS-stimulated RAW264.7 macrophages

Nguyen Xuan Nhiem^a, Nguyen Thi Thu Hien^a, Bui Huu Tai^{a,c}, Hoang Le Tuan Anh^a, Dan Thi Thuy Hang^a, Tran Hong Quang^a, Phan Van Kiem^a, Chau Van Minh^a, Wonmin Ko^d, Seungjun Lee^d, Hyuncheol Oh^d, Seung Hyun Kim^{b,*}, and Young Ho Kim^{c,*}

^aInstitute of Marine Biochemistry, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Caugiay, Hanoi, Vietnam

^bCollege of Pharmacy, Yonsei Institute of Pharmaceutical Science, Yonsei University, Incheon 406-840, Korea

^cCollege of Pharmacy, Chungnam National University, Daejeon 305–764, Korea

^dCollege of Pharmacy, Wonkwang University, Iksan 570-749, Korea

*Corresponding author:

Tel.: +82-32-749-4514; fax: +82-32-749-4105; e-mail address: <u>kimsh11@yonsei.ac.kr</u> (Kim, S. H.).

Tel.: 82-42-821-5933; fax: 82-42-823-6566; e-mail address: <u>yhk@cnu.ac.kr</u> (Kim, Y.H)

Abstract

Three new *ent*-kaurane diterpenoids, 7β , 16α , 17-trihydroxy-*ent*-kauran-19-oic acid (1), 7β , 17-dihydroxy- 16α -*ent*-kauran-19-oic acid 19-O- β -D-glucopyranoside ester (2), 7β , 17-dihydroxy-*ent*-kaur-15-en-19-oic acid 19-O- β -D-glucopyranoside ester (3) along with five known compounds, paniculoside IV (4), 16α , 17-dihydroxy-*ent*-kaurane (5), 16β , 17-dihydroxy-*ent*-kaurane (6), 16β , 17-dihydroxy-*ent*-kauran-19-al (7), and 16β , 17-dihydroxy-*ent*-kauran-19-oic acid (8) were isolated from the fruits of *Annona glabra*. Their chemical structures were elucidated by physical and chemical methods. All compounds were evaluated for inhibitory activity against nitric oxide (NO) production in LPS-stimulated RAW 264.7 macrophages. As the results, compound **3** showed potent inhibitory LPS-stimulated NO production in RAW 264.7 macrophages with the IC₅₀ value of 0.01 μ M; compounds **1** and **7** showed significant inhibitory NO production with the IC₅₀ values of 0.39 μ M and 0.32 μ M, respectively.

Keywords: Annona glabra, Annonaceae, ent-kaurane diterpene, anti-inflammatory

Nitric oxide (NO) produced in large amounts by inducible nitric oxide synthase (iNOS) is known to be responsible for the vasodilation and hypotension observed during septic shock and inflammation.¹ The production of NO confers cytostatic or cytotoxic activity on macrophages against microbes and tumor cells.² NO mediates a variety of biological actions ranging from vasodilatation, neurotransmission, inhibition of platelet adherence and aggregation, as well as the macrophage and neutrophil-mediated killing of pathogens.³ Although previous studies have demonstrated that cytokine-induced NO production can lead to eliminate parasites or tumor cells, NO has also been associated to damage of normal cells. Overproduction of NO causes excessive inflammatory response harmful to body in the inflammatory diseases.⁴⁻⁶ They are secreted during the early phase of acute and chronic inflammatory diseases such as asthma, rheumatoid arthritis, septic shock, and other allergic diseases, and during the activation of T cells.⁷

Annona glabra L., belongs to Annonaceae family is a tropical tree growing wild in the America and Asia. It is used in traditional medicine to treat several diseases such as inflammation, and cancer. Phytochemical investigation led to the isolation of numerous acetogenins,⁸ *ent*-kauranes,⁹⁻¹² peptides,¹³ and alkaloids.^{14, 15} In addition, compounds exhibited anticancer,^{12, 16} anti HIV-reserve transcriptase,¹¹ and antimalarial activities.¹⁴ In the present study, three new along with five known *ent*-kaurane diterpenoids were isolated from the fruits of *A. glabra*. All compounds were evaluated for inhibitory against NO production in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.

The fruits of *A. glabra* were collected in Ho Chi Minh city, Vietnam, in May 2013, and authenticated by Dr. Bui Van Thanh, Institute of Ecology and Biological Resources, VAST, Vietnam. A voucher specimen (AG1605) was deposited at the Herbarium of Institute of Marine Biochemistry, VAST, Vietnam. The dried fruits of *A*.

glabra (4.0 kg) were extracted with MeOH ($3 \times 5 \text{ L}, 50^{--}$) under sonication for 1 h to yield 300.0 g extract after evaporation of the solvent. This extract was suspended in H₂O (2.0 L) and successively partitioned with *n*-hexane, CHCl₃, and ethyl acetate (EtOAc) to obtain the *n*-hexane (AG1, 51.0 g), CHCl₃ (AG2, 190.5 g), EtOAc (AG3, 3.5 g), and H₂O (AG4, 54.0 g) extracts after removal of the solvents *in vacuo*. Using various chromatographic resin and isolation techniques, eight *ent*-kaurane-type diterpenoids were isolated.¹⁷

Compound 1¹⁸ was obtained as a white amorphous powder. The HR-ESI-MS analysis revealed the molecular formula to be $C_{20}H_{32}O_5$, with a pseudo ion peak at m/z375.2159 $[M+Na]^+$ (Calcd. for C₂₀H₃₂O₅Na: 375.2142). The ¹H-NMR spectrum of 1 showed the signals for protons of two tertiary methyl groups at $\delta_{\rm H}$ 1.00 (3H, s) and 1.18 (3H, s), one oxymethine at $\delta_{\rm H}$ 3.63 (br s), and one oxymethylene group at $\delta_{\rm H}$ 3.62 (d, J = 11.5 Hz) and 3.72 (d, J = 11.5 Hz). The ¹³C-NMR and DEPT spectra of 1 revealed signals for 20 carbons including one carboxylic, four quaternary (including an oxygenated carbon at $\delta_{\rm C}$ 82.9), four methine, and nine methylene, and two methyl carbons (Table 1). A comparison of the ¹³C-NMR data of **1** to those of related kaurane, 16α , 17-dihydroxy-ent-kauran-19-oic acid¹⁹ suggested that compound **1** possessed the same ent-kaurane skeleton. The HMBC correlations between H-18 (δ_H 1.18) and C-3 $(\delta_{\rm C} 39.2)/{\rm C}-4$ $(\delta_{\rm C} 44.2)/{\rm C}-5$ $(\delta_{\rm C} 48.1)/{\rm C}-19$ $(\delta_{\rm C} 182.0)$ confirmed the positions of both methyl and carboxylic groups at C-4 (Figure 2). The configuration of the methyl group at C-4 was determined to be β by the observation of NOESY correlation between H-18 $(\delta_{\rm H} 1.18)$ and H-5 ($\delta_{\rm H} 1.77$). The HMBC correlations from H-13 ($\delta_{\rm H} 2.08$)/H-15 ($\delta_{\rm H}$ 1.56 and 1.74) to C-16 (δ_C 82.9)/C-17 (δ_C 66.7) confirmed two hydroxyl groups at C-16 and C-17. In addition, the α configuration of hydroxyl group at C-16 was confirmed by comparing the chemical shifts of C-13 ($\delta_{\rm C}$ 46.1), C-16 ($\delta_{\rm C}$ 82.9), and C-17 ($\delta_{\rm C}$ 66.7)

in **1** with those of the corresponding data of the 16β ,17-dihydroxy-*ent*-kauran-19-oic acid²⁰ [$\delta_{\rm C}$ 41.7 (C-13), 79.8 (C-16), and 70.5 (C-17)] and 16α ,17-dihydroxy-*ent*-kauran-19-oic acid²⁰ [$\delta_{\rm C}$ 45.9 (C-13), 81.7 (C-16), and 66.5 (C-17)]. The position of the hydroxyl group at C-7 was determined by the HMBC correlations from H-5 ($\delta_{\rm H}$ 1.77)/H-6 ($\delta_{\rm H}$ 1.98 and 2.11)/H-15 ($\delta_{\rm H}$ 1.56 and 1.74) to C-7 ($\delta_{\rm C}$ 78.1). Moreover, the NOESY correlations of H-7 ($\delta_{\rm H}$ 3.63)/H-14 ($\delta_{\rm H}$ 1.70) and broad singlet signal of H-7, proved the configuration of H-7 to be α (*equatorial* orientation). Consequently, compound **1** was elucidated to be 7β ,16 α ,17-trihydroxy-*ent*-kauran-19-oic acid. The structure of **1** was previously assumed in the barley grain extract by Paul Gaskin *el al.*²¹ using GC-MS analysis. However, the isolation of pure compound and clear elucidation its chemical structure have not been reported to date.

Compound 2^{22} was also obtained as a white amorphous powder. The ¹H-NMR spectrum of **2** showed the following signals: two methyl groups at $\delta_{\rm H}$ 0.99 (3H, s) and 1.22 (3H, s), assigned to the *ent*-kaurane aglycone; one anomeric proton at $\delta_{\rm H}$ 5.42 (1H, d, J = 8.0 Hz), suggested the presence of a sugar moiety. The ¹³C-NMR and DEPT spectra revealed the presence of 26 carbons: one carboxyl, three quaternary, ten methine (including six oxymethine), ten methylene (including two oxymethylene), and two methyl carbons. The ¹H- and ¹³C-NMR data of **2** were similar to those of helikauranoside A,²³ except for the additional hydroxyl group at C-7. The position of hydroxyl group at C-7 was confirmed by HMBC cross peaks from H-5 ($\delta_{\rm H}$ 1.78)/H-9 ($\delta_{\rm H}$ 1.78)/H-6 ($\delta_{\rm H}$ 1.97 and 2.18)/H-7 ($\delta_{\rm H}$ 3.50). Similarly to **1**, the configuration of H-7 in **2** was determined to be α -configuration by a broad singlet of H-7. The HMBC correlations between H-17 ($\delta_{\rm H}$ 3.35) and C-13 ($\delta_{\rm C}$ 39.5)/C-15 ($\delta_{\rm C}$ 42.6)/C-16 ($\delta_{\rm C}$ 44.7) suggested the hydroxyl group at C-17. In addition, the α configuration of hydrogen

atom at C-16 was determined by comparing the chemical shifts of C-12 (δ_C 33.0) C-13 (δ_C 39.5), C-16 (δ_C 44.7), and C-17 (δ_C 67.7) with the corresponding data of 16*α*-ent-kaurane: helikauranoside A [δ_C 32.5 (C-12), 39.5 (C-13), 44.5 (C-16), and 67.7 (C-17)]²³ and 16β-ent-kaurane: 17-hydroxy-16β-ent-kauran-19-al [δ_C 25.8 (C-12), 36.9 (C-13), 43.1 (C-16), and 64.1 (C-17)].²⁰ The HMBC cross peaks from H-18 (δ_H 1.22) to C-3 (δ_C 39.1), C-4 (δ_C 44.7), C-5 (δ_C 49.5), and C-19 (δ_C 178.7) confirmed the carboxyl group at C-4. Acid hydrolysis of **2** (see Experimental) provided the D-glucose (identified as TMS derivatives). In addition, the coupling constant of glc H-1' and glc H-2'; *J* = 8.0 Hz indicated the configuration of hydroxyl group at anomeric carbon in sugar to be β. The position of this sugar at C-19 of aglycone was confirmed by HMBC correlation between glc H-1' (δ_H 5.42) and C-19 (δ_C 178.7). Based on the above evidence, the structure of **2** was elucidated to be 7β,17-dihydroxy-16*α*-ent-kauran-19-oic acid 19-*O*-β-D-glucopyranoside ester.

Compound 3^{24} was obtained as a white amorphous powder. Its molecular formula was determined to be C₂₆H₄₀O₉ by the appearance of the pseudo-ion peak at *m/z* 519.2550 in the HR-ESI-MS (Calcd. for C₂₆H₄₀O₉Na: 519.2565). The ¹H-NMR of **3** showed one olefinic proton at $\delta_{\rm H}$ 5.81 (1H, s) and two methyl groups at $\delta_{\rm H}$ 1.02 (3H, s) and 1.22 (3H, s), suggested the presence of a *ent*-kaurane moiety; one anomeric proton at $\delta_{\rm H}$ 5.42 (1H, d, *J* = 7.5 Hz), assigned to a sugar moiety. The ¹³C-NMR and DEPT spectra revealed the presence of 26 carbons, including 20 carbons of *ent*kaurane-type diterpenoid and 6 carbons of sugar moiety. The ¹H- and ¹³C-NMR data of **3** were similar to those of **2**, except for the additional double bond at C-15/C-16. The HMBC correlations between H-14 ($\delta_{\rm H}$ 1.42 and 2.06)/H-17 ($\delta_{\rm H}$ 4.13) and C-15 ($\delta_{\rm C}$ 132.1) /C-16 ($\delta_{\rm C}$ 148.1); H-15 ($\delta_{\rm H}$ 5.81) and C-7 ($\delta_{\rm C}$ 75.6)/C-8 ($\delta_{\rm C}$ 54.3)/C-9 ($\delta_{\rm C}$ 43.6)/C-14 ($\delta_{\rm C}$ 43.5)/C-16 ($\delta_{\rm C}$ 148.1)/C-17 ($\delta_{\rm C}$ 61.2) confirmed the double bond at C-

15/C-16. The hydroxyl group at C-7 were determined as the same with those of **2**. Consequently, structure of **3** were elucidated to be 7β,17-dihydroxy-*ent*-kaur-15-en-19-oic acid 19-O-β-D-glucopyranoside ester.

The other compounds were characterized as paniculoside IV (4),²⁵ 16 α ,17dihydroxy-*ent*-kaurane (5),⁹ 16 β ,17-dihydroxy-*ent*-kaurane (6),⁹ 16 β ,17-dihydroxy*ent*-kauran-19-al (7),²⁰ and 16 β ,17-dihydroxy-*ent*-kauran-19-oic acid (8),²⁰ (see Figure 1) on the basis of NMR spectroscopic data, which were in good agreement with those reported in the literature.

To evaluate the inhibitory effects of the isolates on production of NO in the LPSstimulated RAW 264.7 macrophages, cells were seeded in the 24-well plates at a density of 5×10^5 cells/mL. After 3 h, the cells were pretreated with various concentrations of compounds and stimulated for 24 h with or without 1 µg/mL of LPS. Nitrite concentration were measured in the supernatant of RAW 264.7 cells by the Griess reaction.²⁶ First, the compounds were examined their cytotoxicity on cells at concentration of 30 µM. After that, each compound was screened its effects on the LPS induced the production of NO in RAW 264.7 cells at concentrations of 3, 10, and 30 μ M since none of significant cytotoxic effects on the cells was found. In absence of both test compounds and LPS, the NO was produced at very low concentration $(3.16 \pm$ 0.27 μ M). LPS markedly induced the NO production by concentration of 14.48 \pm 0.43 μ M. At the concentration of 30 μ M, compounds 1, 3, and 7 potently decreased NO production with the inhibitory percent ranging from 90.0 to 97.6 %; compounds 5, 6, and 8 significantly decreased NO production with the inhibitory percent ranging from 70.4 to 77.4 % (Figure 3). In order to get the IC_{50} values of highly potent inhibitory compounds, dose dependent inhibitory activities were tested. Suitable concentrations of each compound were roughly estimated from screening results and subjected for dose-

dependent examination. As the results, compound **3** showed potent inhibitory LPSstimulated NO production in RAW 264.7 macrophages with the IC₅₀ value of 0.01 μ M; compounds **1** and **7** showed significant inhibitory NO productions with the IC₅₀ values of 0.39 μ M and 0.32 μ M, respectively. Dexamethasone, a well-known antiinflammatory and autoimmune drug, was used as a positive control throughout experiments. It showed the inhibitory NO production with the IC₅₀ value of 0.8 μ M.

In the structure-activity relationship of *ent*-kaurane (**1–8**), the presence of the double bond at C-15/C-16 affected on inhibitory NO production. However, the presence of sugar moiety at C-19 did not affect to the NO production. In previous report, the methanol extract of *A. glabra* leaves showed potential anti-inflammatory activity.²⁷ Moreover, several *ent*-kauranes have been reported to possess inhibitory LPS-induced NO production in RAW 264.7 macrophages.²⁸ In our experiment, compound **3** showed potent inhibitory LPS-induced NO production in RAW 264.7 macrophages with the IC₅₀ value of 0.01 μ M (Table 2). Thus, it is possible to demonstrate that isolated *ent*kauranes might be important anti-inflammatory constituent of this plant. The *in vivo* anti-inflammatory effect of compound **3** need to be further studied.

Acknowledgements

This work was financially supported by Vietnam Academy of Science and Technology (VAST 04.04.13-14). This work was also supported by a grant from the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815), Republic of Korea. The authors are grateful to Mr Dang Vu Luong, Institute of Chemsitry, VAST for recording the NMR and mass spectra.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:.....

References and notes

- Sinha, B.; Eigler, A.; Baumann, K. H.; Greten, T. F.; Moeller, J.; Endres, S. Res. Immun. 1998, 149, 139.
- Wang, C.; Levis, G. B. S.; Lee, E. B.; Levis, W. R.; Lee, D. W.; Kim, B. S.; Park, S. Y.; Park, E. Int. Immunopharmacol. 2004, 4, 1039.
- Ishibe, K.; Yamanishi, T.; Wang, Y.; Osatomi, K.; Hara, K.; Kanai, K.; Yamaguchi, K.; Oda, T. *Fish Shellfish Immun.* 2009, 27, 386.
- 4. Ialenti, A.; Ianaro, A.; Moncada, S.; Di Rosa, M. Eur. J. Pharmacol. 1992, 211, 177.
- Cauwels, A.; Vandendriessche, B.; Bultinck, J.; Descamps, B.; Rogge, E.; Van Nieuwenhuysen, T.; Sips, M.; Vanhove, C.; Brouckaert, P. *Cardiovasc. Res.* 2013, 100, 28.
- 6. Park, J. E.; Abrams, M. J.; Efron, P. A.; Barbul, A. J Surg. Res. 2013, 183, 487.
- Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldawer, L. L. Nat. Rev. Drug Disc. 2003, 2, 736.
- Liu, X. X.; Alali, F. Q.; Pilarinou, E.; McLaughlin, J. L. Phytochemistry 1999, 50, 815.
- 9. Etse, J. T.; Gray, A. I.; Waterman, P. G. J. Nat. Prod. 1987, 50, 979.
- 10. Chen, C. Y.; Chang, F. R.; Cho, C. P.; Wu, Y. C. J. Nat. Prod. 2000, 63, 1000.
- 11. Chang, F. R.; Yang, P. Y.; Lin, J. Y.; Lee, K. H.; Wu, Y. C. J. Nat. Prod. 1998, 61, 437.
- 12. Chen, C. H.; Hsieh, T. J.; Liu, T. Z.; Chern, C. L.; Hsieh, P. Y.; Chen, C. Y. J. Nat. Prod. 2004, 67, 1942.

- Li, C. M.; Tan, N. H.; Zheng, H. L.; Mu, Q.; Hao, X. J.; He, Y. N.; Zhou, J. Phytochemistry 1999, 50, 1047.
- Likhitwitayawuid, K.; Angerhofer, C. K.; Cordell, G. A.; Pezzuto, J. M.; Ruangrungsi, N. J. Nat. Prod. 1993, 56, 30.
- 15. Tsai, S. F.; Lee, S. S. J. Nat. Prod. 2010, 73, 1632.
- Cochrane, C. B.; Nair, P. K. R.; Melnik, S. J.; Resek, A. P.; Ramachandran, C. *Anticancer Res.* 2008, 28, 965.
- 17. The AG2 extract was chromatographed on a silica gel column and eluted with nhexane-EtOAc gradient (100: 1-1: 1, v/v) to obtain four fractions AG2A-AG2D. The AG2B fraction was chromatographed on a silica gel column eluting with nhexane–EtOAc (4:1, v/v) to obtain three fractions AG2B1-AG2B3. The AG2B1 fraction was further chromatographed on an YMC RP-18 column eluting with acetone-H₂O (3 : 1, v/v) to yield 5 (51.0 mg) and 6 (321.0 mg). The AG2D fraction was chromatographed on a silica gel column eluting with nhexane-acetone (2:1, v/v) to obtain three fractions AG2D1-AG2D3. The AG2D1 was chromatographed on an YMC RP-18 column eluting with acetone-water (5 : 1, v/v) to yield 7 (7.0 mg). The AG2D3 fraction was chromatographed on a silica gel column eluting with CH_2Cl_2 -EtOAc (10 : 1, v/v) to yield $\mathbf{8}$ (10.0 mg). The water soluble fraction AG4 was chromatographed on a Diaion HP-20P column (Mitsubishi Chem. Ind. Co., Tokyo, Japan) eluting with water containing increasing concentrations of MeOH (0%, 25%, 50%, 75%, and 100% MeOH) to give four fractions, AG4A-AG4D. The AG4C fraction was chromatographed on a silica gel column eluting with CH_2Cl_2 -MeOH (6 : 1, v/v) to give three fractions AG4C1-AG4C3. The AG4C1 was chromatographed on an YMC RP-18 column eluting with MeOH $-H_2O$ (1 : 1.5, v/v) to yield 1 (5.0 mg). The AG4C2 was chromatographed on a silica gel column eluting with

CH₂Cl₂–EtOAc (10 : 1, v/v) to obtained two fractions AG4C2A and AG4C2B. The AG4C2A fraction was further separated on an YMC RP-18 column eluting with MeOH–H₂O (1 : 1, v/v) to yield **2** (4.0 mg), **3** (3.0 mg), and **4** (6.0 mg).

- 18. **Compound** (1): White amorphous powder; $[\alpha]_D$: -64.9 (*c* 0.1, MeOH); ¹H-NMR and ¹³C-NMR (CD₃OD): see Table 1; HR-ESI-MS found *m/z* 375.2159 [M+Na]⁺ (Calcd. for C₂₀H₃₂O₅Na: 375.2142).
- Jung, H. A.; Lee, E. J.; Kim, J. S.; Kang, S. S.; Lee, J.-H.; Min, B. S.; Choi, J. S. Arch. Pharm. Res. 2009, 32, 1399.
- Wu, Y. C.; Hung, Y. C.; Chang, F. R.; Cosentino, M.; Wang, H. K.; Lee, K. H. J. Nat. Prod. 1996, 59, 635.
- 21. Gaskin, P.; Gilmour, S. J.; Lenton, J. R.; MacMillan, J.; Sponsel, V. M. J. Plant Growth Regul. 1984, 2, 229.
- 22. **Compound** (2): White amorphous powder; $[\alpha]_D$: -40.7 (*c* 0.1, MeOH); ¹H-NMR and ¹³C-NMR (CD₃OD): see Table 1; HR-ESI-MS found *m/z* 521.2732 [M+Na]⁺ (Calcd. for C₂₆H₄₂O₉Na: 521.2721).
- 23. Macías, F.; López, A.; Varela, R.; Torres, A.; Molinillo, J. G. J. Chem. Ecol. 2008, 34, 65.
- 24. **Compound** (3): White amorphous powder; $[\alpha]_D$: -38.5 (*c* 0.1, MeOH); ¹H-NMR and ¹³C-NMR (CD₃OD): see Table 1; HR-ESI-MS found *m/z* 519.2550 [M+Na]⁺ (Calcd. for C₂₆H₄₀O₉Na: 519.2565).
- 25. Harinantenaina, L.; Kasai, R.; Yamasaki, K. Chem. Pharm. Bull. 2002, 50, 1122.
- 26. Altmann, K. H.; Gertsch, J. Nat. Prod. Rep. 2007, 24, 327.
- 27. Siebra, C. A.; Nardin, J. M.; Florão, A.; Rocha, F. H.; Bastos, D. Z.; Oliveira, B. H.; Weffort-Santos, A. M. *Rev. Bras. Farmacogn.* 2009, *19*, 82.

Aquila, S.; Weng, Z. Y.; Zeng, Y. Q.; Sun, H. D.; Ríos, J. L. J. Nat. Prod. 2009, 72, 1269.

Acception

C	_	1		2		3
C	$\delta_{C}^{a,b}$	$\delta_{\rm H}{}^{\rm a,c}$ (mult., Hz)	$\delta_{C}^{a,b}$	$\delta_{\rm H}^{\rm a,c}$ (mult., Hz)	$\delta_{C}^{a,b}$	$\delta_{\rm H}^{a,c}$ (mult., Hz)
1	41.7	0.93 (m)	41.8	0.94 (m)	41.7	1.03 (dd, 3.5, 13.5)
		1.87 (m)		1.88 (m)		1.87 (d, 13.5)
2	20.3	1.44 (m)	20.2	1.45 (m)	20.2	1.44 (dt, 5.0, 10.0)
		1.96 (m)		1.94 (m)		1.96 (m)
3	39.2	1.08 (dd, 4.5, 13.5)	39.1	1.13 (m)	39.1	1.12 (dd, 4.0, 13.5)
		2.17 (d, 13.5)		2.22 (m)		2.22 (m)
4	44.2	-	44.7	-	44.7	-
5	48.1	1.77 (d, 9.0)	49.5	1.78 (d, 13.0)	48.3	1.78 (m)
6	30.5	1.98 (m)	30.7	1.97 (m)	29.3	1.96 (m)
		2.11 (m)		2.18 (dd, 13.0, 14.	5)	2.23 (m)
7	78.1	3.63 (br s)	78.7	3.50 (br s)	75.6	3.59 (br s)
8	49.0	-	49.8	-	54.3	-
9	51.1	1.43 (d, 7.5)	50.6	1.43 (m)	43.6	1.39 (d, 7.5)
10	40.4	-	40.5	-	40.9	-
11	19.1	1.57 (m)	19.5	1.57 (m)	19.7	1.58 (m)
		1.64 (m)		1.63 (m)		1.64 (m)
12	27.6	1.57 (m)	33.0	1.43 (m)	26.3	1.52 (m)
		1.68 (m)		1.63 (m)		
13	46.1	2.08 (m)	39.5	2.11 (m)	42.2	2.57 (m)
14	37.5	1.70 (dd, 4.0, 12.0)	37.2	1.08 (m)	43.5	1.42 (dd, 7.5, 10.5)
		1.83 (d, 12.0)		1.80 (d, 11.5)		2.06 (d, 10.5)
15	50.1	1.56 (d, 13.5)	42.6	1.12 (m)	132.1	5.81 (s)
		1.74 (d, 13.5)		1.71 (dd, 3.5, 10.0))	
16	82.9	-	44.7	1.94 (m)	148.1	-
17	66.7	3.62 (d, 11.5)	67.7	3.35 (m)	61.2	4.13 (d, 1.0)
		3.72 (d, 11.5)				
18	29.3	1.18 (s)	28.8	1.22 (s)	28.8	1.22 (s)
19	182.0	-	178.7	-	178.6	-
20	16.1	1.00 (s)	16.3	0.99 (s)	16.1	1.02 (s)
19-0	O-Glc					
1'			95.7	5.42 (d, 8.0)	96.6	5.42 (d, 7.5)
2'			74.1	3.38 (m)	74.1	3.38 (m)
3′		7	78.7	3.45 (m)	78.7	3.42 (m)
4'			71.1	3.39 (m)	71.1	3.40 (m)
5'			78.6	3.39 (m)	78.7	3.39 (m)
6'			62.4	3.71(dd, 4.0, 11.5)	62.4	3.71 (dd, 4.0, 12.0)
				3.86 (d, 11.5)		3.85 (dd, 2.0, 12.0)

Table 1. The ¹H and ¹³C-NMR data for compounds 1 - 3

^{3.00} (u, 11.3) 3.85 (dd, 2.0, 12.0) ^{a)}Measured in CD₃OD, ^{b)}125 MHz, ^{c)}500 MHz. Assignments were done by HMQC, HMBC, COSY, and NOESY experiments

1	IC ₅₀ (µM)
1	0.39±0.12
2	>30
3	0.01 ± 0.01
4	>30
5	17.06±0.93
6	6.20±0.47
7	0.32 ± 0.04
8	14.32±1.06
Dexamethasone*	0.80±0.04
*Dexamethasone w	was used as a positi
	,0

264.7 macrophages

Table 2. The inhibitory effects of 1-8 on NO production in LPS-stimulated RAW

14

Figure Legend

Figure 1. Structures of compounds 1–8 from the fruits of *Annona glabra*.

Figure 2. Selected HMBC and COSY correlations compounds 1–3.

Figure 3. Effect of compounds 1–8 on NO production in RAW 264.7 cells. The cells were

treated with various concentrations of compounds (3, 10, and 30 μ M), and then LPS

 $(1 \,\mu g/mL)$ was added and the cells were incubated for 24 h. Dexa, dexamethaxone. The

values represent the means ± SD from three independent experiments.





Figure 2.



Figure 3.



Graphical abstract

New ent-kauranes from the fruits of Annona glabra and their inhibitory

nitric oxide production in LPS-stimulated RAW264.7 macrophages

Nguyen Xuan Nhiem, Nguyen Thi Thu Hien, Bui Huu Tai, Hoang Le Tuan Anh, Dan Thi Thuy Hang, Tran Hong Quang, Phan Van Kiem, Chau Van Minh, Wonmin Ko, Seungjun Lee, Hyuncheol Oh, Seung Hyun Kim and Young Ho Kim

